reports
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare Ho...
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference. To register for the presentatio...
Kohl’s Declares Quarterly Dividend
MENOMONEE FALLS, Wis.--(BUSINESS WIRE)-- The Board of Directors of Kohl’s Corporation (NYSE:KSS) today declared a regular quarterly dividend of $0.50 per share on the Company’s common stock. The dividend is payable June 26, 2024, to shareholders of record at the close of business on June 12, 2024. About Kohl’s Kohl’s (NYSE: KSS) is a leading omnichannel retailer built on a foundation that combines great brands, incredible value and convenience for our customers. Kohl's serves millions of families in our more than 1,100 stores in 49 states, online at , and through our Kohl's App. For a list...
Kohl’s Corporation Holds Annual Shareholders Meeting
MENOMONEE FALLS, Wis.--(BUSINESS WIRE)-- Kohl’s Corporation (NYSE:KSS) (“Kohl’s” or the “Company”) today held its annual shareholders meeting. Following are the preliminary results for the five proposals voted upon by shareholders: Kohl’s shareholders elected Wendy Arlin, Michael J. Bender, Yael Cosset, Christine Day, H. Charles Floyd, Thomas A. Kingsbury, Robbin Mitchell, Jonas Prising, John E. Schlifske, Adrianne Shapira, and Adolfo Villagomez to the board of directors for one-year terms, with an average vote in favor of more than 96 percent of the votes cast; The advisory vote to appr...
Stryve Foods, Inc. Reports Fiscal 2024 First Quarter Results
Stryve Foods, Inc. Reports Fiscal 2024 First Quarter Results Retail Sales Velocity Increasing +23.2% Year-over-Year1Improved Adj. EBITDA Loss by 35.2% Year-over-Year3Reiterating Net Sales Guidance Range of $24M to $30M PLANO, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snacking platform and leader in the air-dried meat snack industry in the United States, today reports financial and operating results for the three months ended March 31, 2024. Q1 2024 – Improved Mix and Growing MomentumThe Company has continue...
Stryve Foods, Inc. Announces Timing of Fiscal 2024 First Quarter Resul...
Stryve Foods, Inc. Announces Timing of Fiscal 2024 First Quarter Results PLANO, Texas, May 12, 2024 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snack and eating platform disrupting traditional consumer packaged goods (CPG) categories, and a leader in the air-dried meat snack industry in the United States, today announces that it will release its fiscal 2024 first quarter results on Tuesday, May 14, 2024, after the market closes. In conjunction with the release, the Company has scheduled a conference call that will be hosted at 4:3...
- Jonathan Chaplin
SATS: model update
This note covers updates to the model following consolidated EchoStar results. We increased service revenue and EBITDA. Our free cash flow is up very modestly. The company has five to seven months to raise capital. We updated our valuation to $95 / share. We will have another update out once we get the Dish, DBS & Hughes 10-Qs.
- Jonathan Chaplin
EchoStar: Quick thoughts following the call
In this brief note, we cover: 1) securitizable spectrum value; 2) when cash runs out; 3) the implications of the DBS lawsuit for raising new capital; 4) operating improvements in prepaid wireless; 4) progress on cost savings; 5) preliminary thoughts on a new strategy in postpaid wireless.
- Jonathan Chaplin
SATS 1Q24 Quick Take: Operating trends fine; focus will be on capital ...
Operating results were generally a bit better than expected. The Company appears to be doing what it can to preserve cash. The cash burn was $100MM higher than we expected and $200MM higher than consensus expected. We estimate that the Company has enough cash to get through the next two quarters, but barely.
AbCellera Reports Q1 2024 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “We continue to execute on advancing our internal pipeline, completing capital investments in forward integration, and expanding strategic partnerships,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “This quarter, presentations on our T-cell engager platform, which includes our highly differentiated CD3 panel, demonstrated how we can repeatedly generate...
Harvard Bioscience Announces First Quarter 2024 Financial Results
Harvard Bioscience Announces First Quarter 2024 Financial Results Strong gross margin performance and focus on efficiency to support ongoing investments in growth HOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, “As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong prior year comparison. Despite these headwinds, we were pleased to deliver gross margins of ...
Sarepta Therapeutics Inc: 1 director
A director at Sarepta Therapeutics Inc sold 3,635 shares at 140.000USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
- Blair Levin
NSR Policy: ACP’s Perils of Pauline
In this Weekend Update, we review the multiple activities affecting the prospects for an ACP extension, including one legislative solution that was pulled from a mark-up, a Senate hearing on the subject, and an effort to attach an extension to FAA reauthorization. Our bottom line remains: 1. With the ACP funds about to run out, recipients in May or June are likely to start having to make hard choices about what they are willing to pay for. 2. We agree with the consensus in government and indus...
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL), (“Viking”), and (“ArrowMark”) announced today that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies. The first two programs will be in the area of immunology. The collaboration brings together Viking and ArrowMark’s expertise in early-stage investing and company creation with AbCellera’s for discovering and developing antibody medicines. Under the collaboration, ArrowMark and Viking will lead the initial process of program selection, followed by ...
Kohl's Continues Mental Health Support with $200,000 Donation to the N...
MENOMONEE FALLS, Wis.--(BUSINESS WIRE)-- (NYSE: KSS) announced today a $200,000 commitment to the over two years in support of reducing stigmas around mental health and providing more resources for youth and BIPOC communities in the Milwaukee area. Kohl’s renewed support, which comes on the first day of Mental Health Awareness Month, aims to increase access to the crucial mental health services that NAMI Southeast Wisconsin provides to local families, and builds on the company’s continued commitment to mental health and well-being. “Kohl's is proud to extend our partnership with NAMI South...
- Blair Levin
NSR Policy: The Interconnections of ACP, Spectrum, Title II, and the S...
In this weekend update, we reconsider our initial takes on several events last week and how they could be affected by events this week. Specifically, we look at the interplay of the FCC’s Title II Order, the Second Circuit opinion upholding New York State’s mandate for ISPs to offer low-income households a low-cost broadband offering, Senator Cantwell’s draft spectrum bill, and how all are affected by the end of ACP funding in the next few weeks.
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Ca...
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register . Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the a...
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
ARDX ARDELYX INC
UTHR UNITED THERAPEUTICS CORPORATION
GTHX G1 THERAPEUTICS
SWTX SPRINGWORKS THERAPEUTICS
- Blair Levin
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.